Published in Health Business Week, November 18th, 2005
"Our progress over the last quarter has been significant," stated Biophan CEO Michael Weiner. "We successfully executed a number of the key strategic initiatives and made substantial progress in a number of new areas. Among the quarter's milestones were the closing of major technology licensing, equity investment, and favorable financing agreements that validated our business strategy, technology portfolio, and development programs."
The results of operations for the 3 months ended August 31, 2005 reflect a net loss of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.